BTS
PDLI

BB&T Securities’s PDL BioPharma, Inc. PDLI Stock Holding History

BB&T Securities’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,200
Closed -$94.5K – 991
2013
Q4 		$94.5K Sell
11,200
-3,200
-22% -$27K ﹤0.01% 879
2013
Q3 		$115K Hold
14,400
– – ﹤0.01% 800
2013
Q2 		$111K Buy
+14,400
New +$112K ﹤0.01% 777

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BB&T Securities's PDLI Position: Q1 2014 in Review

BB&T Securities sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 11,200 shares — an estimated $94.5K sold.

BB&T Securities first reported a position in PDLI in Q2 2013 and held it in 3 quarters. The position peaked at $115K in Q3 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • BB&T Securities reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • BB&T Securities sold 11,200 PDL BioPharma, Inc. shares in Q1 2014, an estimated $94.5K.
  • BB&T Securities first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 3 quarters.
  • BB&T Securities's PDL BioPharma, Inc. position peaked at $115K in Q3 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on BB&T Securities's 13F filing for Q1 2014, filed 15 Apr 2014.